Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TC-220
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : TAE Life Sciences
Deal Size : Undisclosed
Deal Type : Agreement
TAE Life Sciences Signs Biddle Sawyer to Manufacture Boronated TC220 Drug for BNCT Cancer Treatment
Details : Under the agreement, Biddle will serve as the exclusive supplier of TC220, a proprietary boronated amino acid analog developed by TAE Life Sciences to support BNCT cancer treatment.
Brand Name : TC220
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 15, 2023
Lead Product(s) : TC-220
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : TAE Life Sciences
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?